Cancer classification using the Immunoscore: a worldwide task forceJérôme Galon, Noriyuki Sato, Franck Pagès et al.|Journal of Translational Medicine|2012Cited by 803
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaUğur Şahin, S. Al-Batran, Kai Wiechen et al.|Annals of Oncology|2021Cited by 357
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyÖ. Türeci, Martin Schüler, Uğur Şahin et al.|Annals of Oncology|2019Cited by 244
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaRüdiger Hehlmann, Aloïs Gratwohl, Ute Berger et al.|Blood|2007Cited by 168
Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants.Christoph Huber, H. Wächter, Dominik Fuchs et al.|The Journal of Immunology|1983Cited by 153